Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 3/20 | 0.48 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.48 |
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.47 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.40 |
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.39 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | PEPD | P12955 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2136520 | 0.97 | — | — | |
| Butane SCHEMBL28852801 | 0.85 | ALDH1A1 (0.44) | ALDH1A1GAAMAPK1PEPDCYP3A4 | |
| Phosphoric Acid SCHEMBL29102150 | 0.85 | CA1 (0.52) | ALDH1A1GAAMAPK1PEPDCYP3A4 | |
| SCHEMBL38659710 | 0.85 | ALDH1A1 (0.42) | ALDH1A1GAAMAPK1PEPDCYP3A4 | |
| SCHEMBL218054 | 0.80 | TDP1 (0.67) | ALDH1A1GAAMAPK1CYP3A4LMNA | |
| SCHEMBL10906846 | 0.79 | CA2 (0.67) | ALDH1A1GAAMAPK1PEPDCYP3A4 | |
| Phenylhydrazine SCHEMBL28961300 | 0.78 | TDP1 (0.74) | ALDH1A1GAAMAPK1CYP3A4LMNA | |
| Hydrochloric Acid SCHEMBL30096476 | 0.75 | TDP1 (0.53) | ALDH1A1GAACYP3A4LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL31628644 | 0.75 | TDP1 (0.53) | ALDH1A1GAACYP3A4LMNACYP1A2 | |
| Hydroquinone SCHEMBL153882 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122054801-A | Solar cell, preparation method thereof, photovoltaic module, power utilization device and power generation device | 宁德时代新能源科技股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-122054801-A | Solar cell, preparation method thereof, photovoltaic module, power utilization device and power generation device | 宁德时代新能源科技股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-118027130-A | Steroid indole derivative and preparation method and application thereof | 长治学院 | 2024-05-14 | — | — | CN | disclosed |
| CN-117327065-A | Carbazole derivatives as dopamine D2/3 receptor modulators | 北京大学 | 2024-01-02 | — | — | CN | disclosed |
| CN-110218161-A | A kind of preparation method aligning substituted phenylhydrazines hydrochloride | 河北民族师范学院 | 2019-09-10 | — | — | CN | disclosed |
| EP-2875014-B1 | ANTI-MUCUS DRUGS AND USES THEREFOR | UNIV WASHINGTON (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9187470-B2 | Anti-mucus drugs and uses therefor | WASHINGTON UNIVERSITY (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150183777-A1 | ANTI-MUCUS DRUGS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-02 | — | — | US | disclosed |
| EP-2875014-A2 | ANTI-MUCUS DRUGS AND USES THEREFOR | Washington University (US) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014015056-A2 | ANTI-MUCUS DRUGS AND USES THEREFOR | WASHINGTON UNIVERSITY (US) | 2014-01-23 | — | — | WO | disclosed |
| US-20070112037-A1 | Pyrazole Derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-7183306-B2 | Pyrazole derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| EP-1567503-A1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20040116475-A1 | Pyrazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| WO-2004050632-A1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112037-A1 | Pyrazole Derivatives | CYP11B2, CYP11B1, CYP3A43 | GAA 4322/4885PTGS2 1780/4885CA2 3227/4885 |
| US-20150183777-A1 | ANTI-MUCUS DRUGS AND USES THEREFOR | MAPK13, MAPK11, MUC1 | GAA 651/4885PTGS2 621/4885CA2 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.